New Low-Field MRI could sharpen breast cancer detection
NCT ID NCT05486520
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new way to take MRI images of the breast using a very low magnetic field. The goal is to see if this method can produce clearer pictures of breast cancer. About 40 women with benign or malignant breast tumors will be scanned, and the results will be compared to standard mammograms, ultrasounds, and regular MRIs. The new MRI is for research only and will not be used to guide treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2022
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
20 to 80 years
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Informed consent will be obtained from the adult volunteer subjects by the principal investigator, the coinvestigators, or the study staff prior to the imaging session. The investigator obtaining consent will explain in detail the protocol of the study, its purpose, and potential benefits to the society. * Subjects will be informed about the minimal risks of ultra-low magnetic fields) and of low-frequency nonionizing RF radiation involved in ultra-low field MR imaging. Subjects will also be informed about small space within the magnet. Unlike high-field scanners, there is essentially no sound produced by the imaging gradients, so hearing protection is not required. * Subjects will be informed that if they feel uncomfortable with the study, they can choose to terminate the study at any time. They will be informed that their refusal to participate in the study or choosing to terminate it at some point will have no effect on care and treatment received by them at MGH now or in future. * The subjects will be informed that their personal information will be protected as per the HIPAA guidelines. * The subjects will have at least 15 minutes to consider participation. * Subjects will undergo MR contraindication screening to ensure that they meet the basic inclusion/exclusion criteria for the study and give written informed consent immediately prior to the MR imaging study. * Recruit adult female volunteers of any race or ethnic background, between the ages of 20 to 80, who are either scheduled for breast imaging and/or a percutaneous biopsy. * All efforts will be taken to find interpreters for volunteers who do not understand English, enabling them to be screened and consented with the short-form consent form so that they may participate in this study. Exclusion Criteria: * Exclusion criteria include MR contraindications * Electronic implants such as cardiac pacemakers or perfusion pumps * Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants * Ferromagnetic objects such as jewelry or metal clips in clothing * Pregnant or breast feeding women * A history of uncontrolled seizures * Claustrophobia * Any greater than normal potential for cardiac arrest * Subjects less than 18 years of age or over 80 years of age.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast benign are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Spinal fluid may hold clues to breast cancer brain spread
- DNA vaccine aims to train body to fight breast cancer
- Engineered immune cells take on hard-to-treat breast cancer in new trial
- Real-World palbociclib use under the microscope in sweden
- Stress relief before cancer treatment may ease symptoms
- Bacteria bombs target stubborn tumors in new cancer combo trial